AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP

Law360, New York (October 24, 2013, 4:43 PM ET) -- AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market for 12 years.



AARP, which represents Americans 50 and older and their families, sent a letter to U.S. Trade Representative Michael Froman saying the U.S. should not sign onto a TPP agreement that binds it to a 12-year market exclusivity period for branded biologic medicines, which can be used to treat diseases like cancer and...

To view the full article, register now.